Mar 22, 2022 / 06:15PM GMT
Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division - MD & Senior Analyst
Hi. This is Paul Knight at KeyBanc Capital Markets. I'm the life science analyst. When -- similar format today, there will be a room for questions on the chat that you could submit on your screen or e-mail myself at paul.r.knight.
I think Tom wants to make some opening comments, and also today, Gerard Brophy, who's Head of the bioproduction unit at Avantor. As many of you know, we've been doing a lot of work in this area over the past several years. It's certainly a high-growth area and been a focus of M&A for Avantor. So an exciting year, many years ahead, we believe, in terms of biologic production in the industry.
But Tom, I'll let you start with some opening remarks, and I know Ger wants to -- will do the same.
Thomas A. Szlosek - Avantor, Inc. - Executive VP & CFO
Okay. Appreciate it. Thanks, Paul. So I just want to remind the attendees a little bit about Avantor and also reiterate our '22 financial guidance. So we're an $8 billion
Avantor Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript
Mar 22, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers